Cerveau Technologies, Inc. and Nihon Med-Physics Co., Ltd. Announce Manufacturing Service Agreement for [18F]MK-6240 in Japan

TOKYO–(BUSINESS WIRE)–Cerveau Technologies, Inc. (Cerveau) and Nihon Medi-Physics (NMP), a leading company for radiopharmaceuticals in Japan, today announced that they signed a manufacturing service agreement, in which Cerveau grants NMP the right to manufacture [18F]MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent. This will facilitate clinical studies assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s Disease.